Doctor of Osteopathy Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Adam Jacobs

Rheumatology Boca Raton, FL Doctor of Osteopathy

NPI 1689293151 CMS profile 11426897

1050 Nw 15Th St Ste 212A, Boca Raton, FL 33486

Open in the dashboard

General payments

$7,903

201 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Adam Jacobs of Boca Raton, FL is reported in the CMS Open Payments database as having received $7,903 across 201 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 68th percentile of Rheumatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,251 91
2024 General $3,129 72
2023 General $1,378 32
2022 General $145 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Adam Jacobs
  • Rheumatology median
  • Middle half of Rheumatology
  • National median

In program year 2025, general payments to Adam Jacobs were reported at $3,251. Among 4,454 Rheumatology profiles paid that year, the median was $903 and the middle half received between $171 and $2,775.

Show as a table
Year Adam Jacobs Rheumatology median Middle half National median
2019 $0 $744 $153–$2,687 $163
2020 $0 $462 $98–$2,027 $114
2021 $0 $531 $101–$2,153 $132
2022 $145 $627 $125–$2,303 $149
2023 $1,378 $741 $145–$2,524 $160
2024 $3,129 $830 $166–$2,660 $164
2025 $3,251 $903 $171–$2,775 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Genzyme Corporation $1,535 12 payments
  2. Amgen Inc. $1,319 46 payments
  3. AbbVie, Inc. $1,133 31 payments
  4. Janssen Biotech, Inc. $850 17 payments
  5. AstraZeneca Pharmaceuticals LP $554 13 payments
  6. UCB, Inc. $542 24 payments
  7. GlaxoSmithKline, LLC. $403 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $254 4 payments
  9. Sobi, Inc $208 6 payments
  10. Mallinckrodt Hospital Products Inc. $153 2 payments
  11. Other $953 35 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,639 198 payments
  2. Education $264 3 payments
Products named General payments · program years 2022–2025
  1. KEVZARA $2,021 16 payments
  2. TREMFYA $807 15 payments
  3. RINVOQ $783 24 payments
  4. EVENITY $632 25 payments
  5. SAPHNELO $433 12 payments
  6. SIMPONI ARIA $412 5 payments
  7. Bimzelx $298 15 payments
  8. BENLYSTA $279 10 payments
  9. TAVNEOS $278 5 payments
  10. Prolia $245 18 payments
  11. Other $2,231 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

91

Median for Internal Medicine: 777

Drug cost

$1,262

Median for Internal Medicine: $73,373

Branded share of claims

26.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Duloxetine Hcl Generic 22 $562
Hydroxychloroquine Sulfate Generic 11 $293
Methotrexate Methotrexate Sodium Brand 24 $227
Celecoxib Generic 11 $111
Prednisone Generic 23 $69

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEVZARA
  • GENZYME CORPORATION $742
$742 — —
RINVOQ
  • AbbVie, Inc. $366
$366 — —
TREMFYA
  • Janssen Biotech, Inc. $265
$265 — —
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $219
$219 — —
BENLYSTA
  • GlaxoSmithKline, LLC. $165
$165 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

201 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Rheumatology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record